CelularityvsUnitedHealth

CELU and UNH stock compared: price, dividend, valuation and results, from SEC filings.

UNH

UnitedHealth Group Incorporated

$349.91

Value $318B

-10.21%
UNH's page

Celularity (CELU) has a market value of $16M and UnitedHealth (UNH) $318B. Over the last year, with dividends, CELU moved -68.2% and UNH +12.1%. Dividend yield: CELU none, UNH 2.59%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CELU$16M

    UNH$318B

    UNH is 20,259 times CELU

  • Revenue, 12 months

    CELU$19M

    UNH$450B

    UNH is 24,090 times CELU

  • Net income, 12 months

    CELU-$46M

    UNH$15.9B

  • Operating margin

    CELU-264.3%

    UNH5.3%

    269.6 points apart

  • ROIC

    CELU–

    UNH11.3%

  • P/E

    CELU–

    UNH20.0

  • Dividend yield

    CELU0.0%

    UNH2.6%

    2.6 points apart

  • 5-year return

    CELU-99.3%

    UNH-14.7%

    84.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CELU-99.3%

UNH-14.7%

05010015020222023202420252026
Returns by period
PeriodCELUWith dividendsUNHWith dividends
1 year since November 17, 2025-68.2%Price -68.2%+12.1%Price +9.2%
3 years since November 17, 2023-77.0%-38.7% a yearPrice -77.0%-30.5%-11.4% a yearPrice -34.8%
5 years since November 17, 2021-99.3%-63.0% a yearPrice -99.3%-14.7%-3.1% a yearPrice -22.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CELUCelularityUNHUnitedHealth

Valuation

CELUUNH
Valuation
Price$0.48$349.91
Market value$16M$318B
Enterprise value (EV)$39M$363B
P/E–20.0
P/E, 5-year median–25.0
P/B–3.1
EV/EBIT–15.2
Free cash flow yield–7.2%

Results and growth

CELUUNH
Results and growth
Revenue, 12 months$19M$450B
Net income, 12 months-$46M$15.9B
Free cash flow, 12 months–$22.8B
Earnings per share, 12 months-$1.69$17.52
Revenue growth, year on year-51.0%11.8%
Revenue growth a year, past+13.2%over 5 years+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

CELUUNH
Margins and returns on capital
Gross margin19.2%88.3%
Operating margin-264.3%5.3%
Net margin-245.7%3.5%
ROIC–11.3%
ROE–15.5%

Balance sheet

CELUUNH
Balance sheet
Cash$10M$28.5B
Total debt$61M$74.3B
Net debt / EBITDA–1.6
Interest cover-5,480.9×6.2×

Dividends and buybacks

CELUUNH
Dividends and buybacks
Dividend yield–2.6%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield–1.8%
Shareholder yield–4.3%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CELU or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, Celularity or UnitedHealth?

By market value, UnitedHealth ($318B) is about 20,259.4 times Celularity ($16M), at today's prices.

How did CELU and UNH stock do over the last 5 years?

Since November 17, 2021, CELU's price moved -99.3% and UNH's -22.1%. With dividends: CELU -99.3% (-63.0% a year), UNH -14.7% (-3.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, CELU or UNH?

The dividend yield at today's price is none for Celularity and 2.59% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

Which has the higher profit margins, Celularity or UnitedHealth?

Over the last twelve months, the net margin was -245.7% for Celularity and 3.5% for UnitedHealth, and the operating margin -264.3% and 5.3%. Revenue was $19M and $450B.

Which is the better investment, Celularity or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.